Magtrace®

A simple solution for breast cancer staging

Iron oxide. Sugar. Salt. Water. Four simple ingredients that together provide a safe and flexible way to stage early breast cancer, without compromising on clinical effectiveness1.

Particles optimised for nodes

The tiny particles are optimised for migration and uptake in the lymph nodes, providing a clear signal as well as visual guidance when performing sentinel node biopsy procedures2.

Everything you need. Any time you need it.

Magtrace® is a single injection, dual-tracer that works in minutes. It remains in the sentinel lymph nodes for at least a month, so you can plan injections to suit you and your patient.

Put patient comfort first

Eliminate patient pain by injecting Magtrace® in the OR after anaesthesia. If injected days before surgery, Magtrace can cause less discomfort than radioactive isotopes.

No benefit? No surgery. No brainer.

The 30-day injection window means that some DCIS patients could avoid unnecessary lymph node surgery, as surgery only needs to proceed after pathology has confirmed there is a benefit in doing so.

Particles optimised for nodes

The tiny particles are optimised for migration and uptake in the lymph nodes, providing a clear signal as well as visual guidance when performing sentinel node biopsy procedures2.

Everything you need. Any time you need it.

Magtrace® is a single injection, dual-tracer that works in minutes. It remains in the sentinel lymph nodes for at least a month, so you can plan injections to suit you and your patient.

Put patient comfort first

Eliminate patient pain by injecting Magtrace® in the OR after anaesthesia. If injected days before surgery, Magtrace can cause less discomfort than radioactive isotopes.

No benefit? No surgery. No brainer.

The 30-day injection window means that some DCIS patients could avoid unnecessary lymph node surgery, as surgery only needs to proceed after pathology has confirmed there is a benefit in doing so.

Why magnetic tracers?

Magnetic tracers have been designed to simplify breast cancer staging, to make it more convenient and more widely available, without compromising on clinical effectiveness.

  • Accurate

    Clinical trials have shown Magtrace® lymphatic tracer to be non-inferior to the combination of radioisotope +/- blue dyes1.

  • Safe

    No reported allergic reactions or anaphylaxis in over 200,000 cases4.

  • Flexible

    The Magtrace® lymphatic tracer allows you to plan injections weeks ahead of surgery2

  • Radiation-free

    Iron oxide. Sugar. Salt. Water. A simple solution to replace radioactive tracers.

Trusted by experts, demanded by patients

Hear how world-leading physicians are enjoying the truly unique benefits of the Magtrace® lymphatic tracer to provide a more flexible approach to SLNB and avoid surgery when it’s not needed.

Dr. Ashley Simpson
Dr. Anne Peled
Dr. Janette Gomez
Dr. Patricia Clark & Dr. Cindy Mak
Dr. Ashley Simpson
Dr. Anne Peled
Dr. Janette Gomez
Dr. Patricia Clark & Dr. Cindy Mak
Magtrace is a real game-changer to the way we treat breast cancer in the United States.
Dr. Laura Esserman UCSF Breast Care Center
It's life changing for the patient and practice changing for us. It does a great job.
Dr. Lucy De La Cruz MedStar Georgetown University Hospital
Given enough time and dispersement of this information and technology, Delayed Sentinel Node Biopsy will become a standard.
Dr. Shawna Willey Inova Schar Cancer Institute
This is the one product I've seen that provides a real benefit to the patient that is substantial.
Dr. Janette Gomez Allegheny General Hospital
Magtrace is a real game-changer to the way we treat breast cancer in the United States.
Dr. Laura Esserman UCSF Breast Care Center
It's life changing for the patient and practice changing for us. It does a great job.
Dr. Lucy De La Cruz MedStar Georgetown University Hospital
Given enough time and dispersement of this information and technology, Delayed Sentinel Node Biopsy will become a standard.
Dr. Shawna Willey Inova Schar Cancer Institute
This is the one product I've seen that provides a real benefit to the patient that is substantial.
Dr. Janette Gomez Allegheny General Hospital
Magtrace Collaboration
Dr. Kristalyn Gallagher
Holly Miller & Dr. Shawna Willey
Dr. Kelly Hewitt
Magtrace Collaboration
Dr. Kristalyn Gallagher
Holly Miller & Dr. Shawna Willey
Dr. Kelly Hewitt

Backed by data

200,000+

total patients treated5

98.7%

sentinel lymph node detection rate1

2.4

average nodes obtained per patient5

Related products

  1. 1 Pantiora et al (2022) Evolution and refinement of magnetically guided sentinel lymph node detection in breast cancer: meta-analysis. Br J Surg. 2023 Mar 30;110(4):410-419. doi: 10.1093/bjs/znac426 (Featuring 20 comparative studies for the Magseed® marker and guidewires)
  2. 2 Karakatsanis et al (2023) Delayed Sentinel Lymph Node Dissection in Patients with a Preoperative Diagnosis of Ductal Cancer In Situ by Preoperative Injection with Superparamagnetic Iron Oxide (SPIO) Nanoparticles: The SentiNot Study. Ann Surg Oncol. 2023 Jul;30(7):4064-4072. doi: 10.1245/s10434-022-13064-0 (Study featuring 254 patients from 6 hospitals)
  3. 3 Pantiora et al (2023) Magnetic Seed vs Guidewire Breast Cancer Localization With Magnetic Lymph Node Detection: A Randomized Clinical Trial. JAMA Surg. 2024 Mar 1;159(3):239-246. doi:10.1001/jamasurg
  4. 4 Data on file at Endomag. Data correct as of November 2025.
  5. 5 Data on file at Endomag. Data correct as of March 2025. (Internal Meta-Analysis 090724 of Clinical Studies).

Get started with your Magtrace® trial

Give your patients a better standard of breast cancer surgery without the need for radioactivity. Set up a Magtrace® lymphatic tracer evaluation today.

  • Evaluate Magtrace®
  • 185,000+ patients already treated
Arrange your Magtrace trial